Gene Bridges and BASF Sign Collaboration Agreement
News Apr 18, 2007
Gene Bridges GmbH, the recombineering company announced that it has signed a collaboration agreement with BASF AG to use Gene Bridges’ Red/ET recombination technology alongside BASF´s expertise in biotechnology, process development and product application.
Under the terms of the agreement, Gene Bridges will provide bio-molecular engineering for strain optimisation and in return, BASF will be responsible for subsequent screening and product and process development. The new agreement is a significant expansion of previous service projects carried out by Gene Bridges for BASF.
“We are delighted to have reached this agreement with such a major player in the industrial biotechnology sector as BASF,” commented Dr. Harald Kranz, who is jointly responsible for this project at Gene Bridges GmbH.
Dr. Tim Zeppenfeld, who shares responsibility for the project at Gene Bridges GmbH, added: “We feel confident that our know-how combined with BASF´s excellent technical possibilities will result in a significant acceleration of strain development.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.